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Abstract
“One size fits all” is an erroneous paradigm in drug delivery, due to side  
effects/adverse effects and variability observed in drug response. The variability 
is a result of geneotypic variations (variability in genomic constitution) which is 
studied in the branch of science called Pharmacogenomics. The variability in drug 
response is studied by multigene analysis or profiling of whole-genome single 
nucleotide polymorphism (SNP) and is recorded in terms of the pharmacokinetic 
(absorption, distribution, metabolism and elimination) and pharmacodynamic 
(drug-receptor interaction, immune response, etc.) response of the drug. Therefore, 
a foray into this research area can provide valuable information for designing of 
drug therapies, identifying disease etiology, therapeutic targets and biomarkers for 
application in treatment and diagnosis of diseases. Lately, with the integration of 
pharmacogenomics and nanotechnology, a new facade for the diagnosis and treat-
ment of diseases has opened up, and the prescription pattern of drugs has moved 
to pharmacotyping (individualized dose and dosage-form adjusted therapy) using 
nanoplatforms like nanobioconjugates, nanotheranostics, etc.
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1. Introduction
By the end of 1950s, pharmacogenetics had become a more established approach 
for the treatment of diseases. The term ‘pharmacogenetics’ was coined in the year 
1959 by Vogel [1] and can be understood as the scientific study of variation in the 
response of drugs due to heredity of individuals [2]. Though introduced quite early, 
pharmacogenomics caught attention in the year 1997, with advancement in the 
science of gene cloning and genome sequencing it was used in conjunction with 
pharmacogenetics [1]. However, the history of pharmacogenetics can be traced 
back to 510 B.C. when Pythagoras recognized the dangers of ingesting fava beans 
that resulted in fatal reaction in some individuals, and later on the reaction was 
attributed to the deficiency of G6PD in those individuals [3]. Establishment of the 
rules of heredity by Mendel in 1866 further shaped this field of research alongside 
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publication of Garrod named “Inborn Errors of Metabolism”. Other studies which 
further supported the science of pharmacogenetics include occurrence of unusual 
reactions to drugs on the basis of biochemical individuality studied by JBS Haldane, 
inborn variation in individuals for phenylthiocarbamide, atropine esterase activity 
in rabbits and occurrence of hemolytic disease in American soldiers of only African 
descent upon administration of the drug primaquine [3, 4]. Genetic deficiency of 
butyryl-cholinesterase (which resulted in death of individuals upon administration 
of succinylcholine injection for anesthesia) and N-acetyltransferase (responsible 
for metabolism of the drug isoniazid) further supported the concept of pharmaco-
genetics [4]. Further investigations also indicated presence of genetic differences 
at the level of human populations in addition to that of individuals. For example, 
Africans and Chinese have been found to be slow metabolizers for debrisoquine 
than Europeans and there is absence of alcohol metabolizing capacity in East Asians 
[4]. Knowledge of pharmacogenetics has thus given a new dimension to diagnosis, 
wherein physicians can individualize treatment for each patient, thereby producing 
better therapeutic response to therapy.
Genes play a vital role in the metabolism of many drugs; cytochromes P450 rep-
resent a major family of genes which are involved in regulation of metabolism of the 
drugs. Cytochromes P450 CYP3A4, CYP2C9, CYP2C19, and CYP2D6 are encoded 
by different genes and play a significant role in metabolism. A major fraction of the 
population lacks either of CYP2D6 or CYP2C19 because of the presence of inacti-
vating genetic polymorphisms [1, 5]. Mere appearance of these inactive forms of 
variant alleles brings about the absence of activity affecting the metabolism of cer-
tain drugs metabolized by these enzymes. On the other side, a fraction of popula-
tion have been found to have higher CYP2C19 or CYP2D6 activity than the normal, 
and are termed as ultrarapid metabolizers [6, 7]. Phase II metabolism involves 
conjugation reactions with sulphate, methyl, or glucuronic acid groups which are 
aided by certain enzymes and presence or absence of these enzymes affect Phase II 
metabolic reactions. For instance, it has been reported that polymorphism affects 
methylation of drug mercaptopurine (~0.3% of population lacks thiopurine meth-
yltransferase) [8]. Certain genetic polymorphisms also cause structural alterations 
in drug targets apart from drug metabolism. Specific receptors on the surface of 
cells, enzymes, ion channels or transporters can be construed as drug targets. The 
gene VKORC1, encodes for Vitamin K epoxide reductase to which warfarin and 
other coumarin anticoagulants bind and has shown to exhibit extensive genetic 
polymorphism thus affecting drug response. This enzyme regulates regeneration 
of reduced vitamin K during the blood coagulation process [9]. Besides, indication 
of variation in drug metabolism and drug targets, pharmacogenetics also helps to 
discover adverse drug reactions due to exaggerated drug response, interaction with 
an inappropriate target or an inappropriate immune response to the drug [1].
2. Role of pharmacogenetics in diagnosis
Pharmacogenetics, including molecular genetics, has an essential role in the 
clinical management of diseases. Genetic testing has unfolded facts related to 
metabolism of drugs, and designing of personalized therapeutic regimens for safer 
and more efficient treatment with improved clinical outcomes. Practice of prescrib-
ing personalized medicine is gaining importance in healthcare as it helps to make 
therapeutic decisions based on individual characteristics, including genetic traits, 
quality of life, and environmental factors. Development in this field of science 
can provide important inputs which can be beneficial in diagnostics in cardiology 
(hemodynamics and electrophysiology), neurology, and oncology. Abundantly 
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prescribed medications like Platelet aggregation inhibitors (PAIs), oral anticoagu-
lants (OAs), antihypertensive and cholesterol-lowering drugs for cardiovascular 
disease, individual responses and efficacy can vary significantly due to genetic 
diversity. Genetics pharmacology and pharmacogenomics are genetically personal-
ized guided therapies that optimize treatment and reduce toxicity. Genes have a 
significant influence on growth, development, health, and drug metabolism.
Human Genome Project (HGP) finished in 2003 helped to identify disease 
pathophysiology at the molecular level. With progress in bioinformatics and novel 
sequencing technologies for next-generation sequencing (NGS), sequencing of 
human genome has become easier, cost-effective and less time consuming. The 
National Human Genome Research Institute (NHGRI) has launched the DNA 
Elements Encyclopedia (ENCODE) to discover all functional sequences of the 
human genome [11]. Likewise, the Cancer Genome Atlas (TCGA) molecularly 
characterizes over 20,000 primary cancers, identifying and documenting the 
uniqueness of cancer types. 2.5 petabytes of genome, epigenome, transcriptome 
and proteomics data have been generated by TCGA to improve the ability to diag-
nose, treat and prevent cancer [10]. Sequencing disease-related mutant genes in 
many hereditary diseases and also, sequencing of target of disease-related genes can 
provide useful data in treatment of diseases. The PharmGKB base (https://www.
pharmgkb.org/) and PGRN hub database (http://www.pgrn.org/) are coordinated 
with the Pharmacogenomics Research Network (PGRN) to impact treatment 
[11, 12]. The database from Pharmacogenomics PharmaGKB and Very Important 
Pharmacogene (VIP) link additional external resources to visualize genotypes, 
molecules, and clinical information of disease pathway representations to select the 
optimal regimen [11].
Adjustment of chemotherapeutic dosage according to genetic profile of individ-
uals can also be achieved accordingly, which can help reduction of dose, side effects 
and toxicity. Genetic markers, HLA-B * 15:02 and HLA-B * 57:01 have been identi-
fied via HLA allelic testing of prescription drugs such as abacavir, and carbamaze-
pine, respectively, but most genetic markers rarely reach such a dichotomy. The 
variability in clopidogrel response due to loss of CYP2C19 allele function is 12%. 
Heritable fluctuations are estimated to be 72%. This means that other genes are also 
involved in CYP2C19 variability in response to clopidogrel.
Additionally, the VKORC1 and CYP2C9 alleles account for less than 40% of dose 
variability upon administration of warfarin, further, rare mutations in genes have 
recently been reported, which may cause variation of unknown cause. Curtailed 
understanding of relationship of genetic effects and drug response can affect clini-
cians’ and patients’ confidence in genetic testing. It reduces clinical decision making 
for prediction of probabilities and possibilities. Pharmacological genomics-based 
clinical trials enhance drugs’ development by establishing a correlation between 
genetic profile and patient outcome during the early stages of clinical trials. Phase 
III studies can be extended to individuals who have a genetic predisposition to safely 
and effectively use developmental drugs.
3. Pharmacogenetic tools to identify genetic variants
The three major approaches to detecting genetic mutations associated with drug 
responses are “candidate mutations”, genome-wide association studies (GWAS), 
and whole-exome sequencing (WES). Genome-wide association studies (GWAS) 
is related to complete genome screening of hundreds of thousands of single nucleo-
tide polymorphisms (SNPs) rather than candidate genes. Whole-exome sequenc-
ing identifies variants in the genome’s protein-encoding regions and analyzes the 
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genomic regions most likely to contain pathogenic variants and are being used 
frequently in pharmacogenetics of drug metabolism [13].
3.1 Genotyping in polymorphism
SNPs have become an essential marker for genetic research. Genotyping meth-
ods are mainly used to identify polymorphisms or SNPs that have great potential for 
developing new diagnostic markers that allow pharmaceutical and biotechnology 
research to identify genetic variation. Polymorphism can be detected via micro-
fluidic devices and allows for very rapid fragment separation by high performance 
liquid chromatography and capillary electrophoresis, enabling detection of bio-
molecules of interest. Genotyping can be applied in the field of diagnostics, drug 
discovery, drug delivery, tissue engineering and bio-nanosensors (“lab-on-a-chip”) 
[16]. High-speed, high-throughput SNP analysis using the innovative biochip 
nanotechnology based platform is an ideal technique for high-resolution mapping 
and population genome research and the development of electronic microarray 
platforms. Moreover, DMET Plus is a chip developed by Affymetrix that covers 1936 
genetic variants (including SNPs and copy number variations) across 231 relevant 
genes. PharmaADME and “Core ADMEGene” comprises of a list of genes and 
genetic biomarkers that can be used to screen pharmacokinetic variability [14].
3.2 Candidate variants
Candidate gene studies help identify the frequency of genetic marker primarily 
SNPs present at a higher frequency among patients and healthy individuals. This 
hypothesis is based on identification of variants of particular genes of interest 
associated with a genotyped trait which will help in their quantitative assessment. 
Moreover, these candidate genes are selected for their functional role in patho-
genesis or their linkage within chromosomal region. The candidate variants test 
determined through SNP test generally estimates the frequency of available disease-
causing variants in individuals known as the non-functional mutations (indirect 
associations). These non-functional mutations exhibit strong linkage disequilib-
rium (LD) with direct association’s functional mutations. Researchers have identi-
fied several variants of candidate genes such as VPS35, DNAJC13, HTRA2, NOS3, 
KCNS2, HAPLN4, USP46, SCN4A, TENM4, and FUS, probably under monogenic 
essential tremor conditions. However, their confirmation still requires a lot of 
independent research [15]. The genes NLRP2, FEZ2, CADM2, ANK3, NEK3, NEK7, 
TUBB, ANKRD1, and BRD2 are genetic mutations responsible for the development 
of the bipolar disorder (BD) and their detection in genetic tests will facilitate diag-
nosis. A better understanding of the genes and pathways involved is also needed to 
target genes that can improve treatment strategies. Further, GWAS and quantitative 
proteomics studies reveal the most significantly upregulated proteins in neural stem 
cells and mature neurons with brain damage [16].
3.3 Genome-wide association studies (GWAS)
Genome-wide association study (GWAS) is a technique that accurately and 
rapidly analyzes samples of the entire genome to determine genetic variation that 
causes the development of disease. It includes a human genome sequence for refer-
ence, a map of human genetic variation, and a computer database with advanced 
interpretation interfaces. Some of the genetic variations (DNA or genome) identi-
fied using GWAS have been shown in Table 1. This information will help in better 






































Pharmacogenes GWAS identified 
reference no
Structure/key points Medical condition Reference
Intronic HMGA2 rs1042725 Intracranial volume Adult height Polymorphism HMGA2 influences the 
expression of the insulin-like growth factor 2 gene (IGF2) 
alongwith pleomorphic adenoma gene 1 (PLAG1)
[17]
Intronic CRHR1 rs17689882 Intracranial volume Encodes corticotrophin-releasing hormone receptor. [18]
Intonic GPCPD1 rs2618516 Occipital lobe surface area Encode protein that hydrolyzes glycerophosphocholine [19]
FBLN2 rs145212527 Hippocampal volume Tissue organization and neuron differentiation [20]
SNVs, LPL, LCAT, APOB, LDLRAP1, 




Genes facilitate receptor-mediated 
endocytosis, recycling, receptor 
regulation, biliary cholesterol 
excretion
Severe hypercholesterolemia [21]




Genes alter net renal sodium balance 
and blood pressure variation





GTR000514111.4 Mutation in these genes may cause 
increased in TGF-β signaling in 
myocyte leading to fibrosis.
Familial Hypertrophic cardiomyopathy [23]
FBN1 rs1036477 and rs2118181 Aortic aneurysm formation Marfan’s syndrome [24]
NKX2–5, GATA-4, TBX5 rs2277923, rs28936670
rs368418329, rs56166237 
rs6489957
The transcription factors for heart 
development and regulation





NOTCH1 acts to suppress the default 
osteoblast mesenchymal flap
The bicuspid aortic valve, califi aortic valve disease [26, 27]
Table 1. 
GWAS identified pharmacogenes and its medical condition.
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asthma, cancer, diabetes, heart disease and mental illness. Genome-wide associa-
tion studies can also help in detection of the risk of drugs for type 2 diabetes, 
Parkinson’s disease, heart disease, Crohn’s disease, prostate cancer, and depression. 
Researchers conducted a genome-wide association study (GWAS) using partici-
pants from two groups: sick and similar people without illness. Their DNA samples 
are collected from participants by taking blood samples or cotton swabs by mouth. 
Certain genetic mutations occur more frequently in sick people as compared to 
non-sick people and thus, these variations are “related” to the disease. It has been 
observed that these genetic mutations identified in the human genome region 
are related to the cause of the disease. At the same time, the disease may not be 
directly linked to the cause of the disease, so, the mutation may be “marked” with 
the variant that actually causes the disease. Therefore, researchers often sequence 
DNA base pairs in that particular region of the genome to detect the actual genetic 
alterations that cause the disease to develop. The complete set of DNA, or each 
participant’s genome, is purified and scanned on an automated laboratory machine 
by placing it on a small chip.
The National Center for Biotechnology Information (NCBI) has developed a 
genome-wide database of association studies. It collects data repositories related 
to various diseases known as databases of genotypes and phenotypes (dbGaP) 
accessible from the NCBI website (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=gap). The GWAS initiative was supported by the National Institutes of 
Health, Pfizer Global Research, and the Genome-wide Association Study (GAIN). 
GAIN is funding various GWAS studies on bipolar disorder, major depression, type 
1 diabetic nephropathy, hyperactivity disorder, schizophrenia, and psoriasis at 
http://www.fnih.org.It can be found at work/past-programs/genetic-association-
Information Network Gain. NIH Institute has also launched a genome-level 
related study at the National Institute of Cardiopulmonary Blood (NLBI) and a 
flamingham gene study in collaboration with Boston University School of Medicine 
for cardiovascular and other chronic disorders. Women’s health studies have been 
contributed to the pharmacogenetics research network to investigate the effects of 
genes on osteoporosis, diabetes, and various responses of individuals to drugs, etc. 
The National Eye Institute and the National Institute of Neurological Disorders also 
pushed the Parkinson’s disease stroke GWAS study.
3.4 Whole-exome sequencing (WES)
Whole exome sequencing, also known as next-generation sequencing (NGS), 
sequences the genome’s protein regions. With this method, researchers can observe 
the effect of phenotypes by sequencing only the genome’s coding regions. 2–3% 
of human exomes represent the entire genome, which is the root cause of approxi-
mately 85% of known disease-related mutants. Exome sequences can efficiently 
identify coding variants and find application in population genetics, genetic dis-
eases, cancer research, and cost-effective alternatives to whole-genome sequencing. 
It also produces a more manageable dataset for faster and easier data analysis than 
the whole genome approach (a sequence of 4–5 Gb per exome versus about 90 Gb 
for the entire human genome). Exon sequencing detects exon encoding variants and 
extends targeted content to provide a more comprehensive view of gene regulation, 
including untranslated regions (UTRs) and microRNAs. The DNA library can be 
created in one day and requires only 4–5 Gb sequences per exome. Illumina DNA 
Prep with Exome Enrichment Kit, AmpliSeq for Illumina Exome Panel, TruSeq DNA 
Exome, TruSight One Sequencing Panels, Nextera DNA Exome, Library Prep Kit 
Selector are exome sequencing kits for analyzing coding regions of genomic variants.
7
Integrated Role of Nanotechnology and Pharmacogenetics in Diagnosis and Treatment of Diseases
DOI: http://dx.doi.org/10.5772/intechopen.97643
In WES procedures, target regions with the fragmentation of genomic DNA are 
captured by hybridization using a solution of biotinylated oligonucleotide probe. 
The captured target sequence is isolated using streptavidin beads and subsequently 
amplified and sequenced after washing and elution. Their quantification helps in 
preparation of DNA libraries for high-quality whole-exome sequencing. Exome 
sequencing is useful in identifying Miller syndrome and rare Mendelian disease 
mutations. The NHLBI “Grand Opportunity” Exome Sequencing Project (GO-ESP) 
in association with Exome Aggregation Consortium (ExAC) helps to identify dis-
eases associated with rare variants for the development of personalized medicine, 
and harmonizing patient-specific treatments.
4. Pharmacogenomic database
Pharmacogenetics is a field that provides information related to drug metabo-
lizing enzymes, drug transporters, drug targets, and mutant genes that code for 
proteins necessary for drug response or toxicity. Next-generation sequencing is car-
ried out by the rapid development of functional genomics that genetically analyzes 
the most essential mutations, gene copies, changes in the number of genomes and 
versatile arrays. These pharmacogenomics efforts help physicians prescribe safer 
and more effective treatments and personalized medications,. The joint clinical 
pharmacology genomics implementation consortium (CPIC, https: //cpicpgx.org/) 
project between the online resources PharmaGKB and Pharmacogenomics Research 
provides guidance on genetic testing to enhance and optimize drug therapy. In 
addition, the NIH-funded Implementing Genomics in Practice (IGNITE) initiative 
and the Dutch Pharmacogenomics Working Group (DPWG) in Europe have been 
developed with a focus on conducting and interpreting genetic testing to guide 
clinical decision-making. These consortia implement pharmacological genom-
ics services in the clinic to update their knowledge according to pharmacological 
genomics guidelines. Some pharmacogenomic database and their attributes have 
shown in (Table 2).
4.1 The pharmacogenomics Knowledge Base (PharmGKB)
The Pharmacogenomics Knowledge Base (PharmGKB), funded by the National 
Institutes of Health and the Pharmacogenomics Research Network (PGRN), a 
joint research consortium, was developed at Stanford University to identify genetic 
mutations that affect drug responses [40]. The PharmGKB website (http://www.
pharmgkb.org) contains genotypes, molecules and clinical knowledge integrated 
into the path representation, as well as additional external links to the all-important 
Pharmacogene (VIP). This is a web-based public repository of genotypic and phe-
notypic information related to the Pharmagenetics Knowledge Base (PharmGKB, 
http: //www.pharmgkb.org), which supports expression, storage, analysis, etc.) 
and distribution of pharmacogenetics data [37, 38]. PharmGKB aims to facilitate 
field research and facilitate the sharing of critical pharmacogenetic datasets. 
Pharmacological genomics can explain the various reactions (side effects and/
or degree of positive response) to a drug due to the presence of specific alleles of 
the gene that explain the hereditary change. PharmGKB organizes data related to 
pharmacodynamics and response to medication, changes in pharmacokinetics, 
changes in molecular and cellular function assays, and changes in gene sequences. 
All datasets are categorized into these five sets and are also associated with related 





Attributes Developed by References
cBioPortal Bioinformatics tools for 
visualization and gene-
based analysis of cancer 
patients’ molecular profiles 
and clinical attributes from 
large clinical trials.
Memorial Sloan Kettering 
Cancer Center (MSKCC) 
Computational Biology 
Center (cBio) is affiliated 
with The Cancer Genome 





CellMiner Enables rapid retrieval of 
activity ratios of over 20,503 
compounds, including 
22,379 genes, 92 proteins, 
360 microRNA transcripts, 
and 102 US Food and Drug 
Administration (FDA) 
approved drugs.
National Cancer Institute 
(NCI) Molecular Therapy 




Connectivity Map The CMAP 2.0 software 
identifies chemicals with 
similar gene profiling 
between the corresponding 
genes, or the gene signature 
previously identified as a 
general gene expression 
modification for one or 
more known compounds 
from the CMAP database. 
The software uses 
up-regulated and down-
regulated query genes 
representing biological 
processes to detect both 
positive and negative 
connectivity compounds.
Broad Institute of MIT, 






Terminology and The 
National Drug File - 
Reference Terminology)
Database as a prescription 
drug resource to provide 
a range of unique diseases 
- drug combinations that 
suggest significant novelty 
potential
Developed by the US 
Department of Veterans 







This is an external database 
developed through the 
eMERGE project which, 
contrary to assisting 
doctors in prescribing, 
determines patient-specific 
information, mainly patient 
data and the new PGx from 
disease drug search engines.
The eMERGEseq initiative 
aims to identify rare 
variants. Partner Healthcare 
(two sequencing centres) 
with the Baylor Medical 
College Human Genomic 
Sequencing Center (HGSC) 
and Broad Institute has 
developed SPHINX 
to develop a series of 
high-impact genes, single 
nucleotide polymorphisms 
(SNVs), And the discovery 
of genomics by identifying 
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4.2 The human cytochrome P450 (CYP) allele nomenclature website
The human cytochrome P450 allele nomenclature (CYP allele) (http://www.
cypalleles.ki.se/) is a web-based analysis of CYP mutant genetic information with 
molecular and clinical effects. Most of the CYPs on the CYP allele website are 
polymorphic enzymes involved in the differentiation of foreign bodies but have 
endogenous functions. The website also contains information related NADPH 
cytochrome P450 oxidoreductase (POR), an electron donor of the CYP enzyme, 
which contains 29 CYP genes, so the POR allele is also a stellar allele nomenclature 
(POR*). This website covers the polymorphic alleles of NADPH cytochrome P450 
oxidoreductase (POR) and 29 CYP enzymes’ CYP2B6, CYP2C9, CYP2C19, and 
CYP2D6 genes. Each CYP allele contains information related to various alleles 
and their nucleotide changes, in vitro and in vivo molecular and functional 
effects [39].
4.3  The human arylamine N-acetyltransferase (NAT) gene nomenclature 
committee
Several genetic mutations related to human arylamine N-acetyltransferase 
(NATgene) in species, humans and other organisms have been identified and the 
allelic nomenclature for the gene has also been recognized. The committee will 
assist in the naming arylamine N-acetyltransferase and also its new arylamine 
N-acetyltransferase allele. The information will be accessible to the international 
scientific community via the Internet [40].
4.4 Transporter database (TP-search)
Homeostatic exchange between endogenous and extrinsic substances such 
as ions, small molecules, macromolecules and drugs and transport proteins 
(transporters) occurs at the systematic, organic, cellular and intracellular 
levels. Genomics, transcriptomics, and proteomics techniques for transporter 
genes in normal cellular processes and various pathologies have been integrated 
to develop the Human Transporter Database (HTD) (http://htd.cbi.pku.edu.
cn) which indicate the relationship between expression patterns exhibited by 
transporter genes and polymorphisms and their ligands. Study on a human 
transporter involved in many fundamental biological processes, including 
oxidative phosphorylation and myocardial contraction, has shown the link 
between Mendel’s laws and complex diseases. In particular, HTD serves as a 
well-organized interface to facilitate the research community to retrieve detailed 
molecular and genetic information for transporters and develop personalized 
medicine [41].
4.5 UGT alleles nomenclature page
The uridine diphosphate glucuronosyltransferase (UGT) enzyme involved 
in the glucuronidation of the target substrate makes foreign substances and 
other endogenous compounds water-soluble for renal excretion. The UGT Allele 
Nomenclature page describes the UGT1A1 haplotype. Developmental hyperbili-
rubinemia causes kernicterus or the accumulation of bilirubin in brain tissue. As a 
result of this, neurological damage occurs which is irreversible, resulting in severe 
disability or death. Bilirubin levels can be controlled by intensive phototherapy, the 




5. Role of nanotechnology in pharmacogenomics based diagnosis
Nanobio-labeling is an important tool in biomarker research that uses water-
soluble, biocompatible, fluorescent and stable nanomaterials to label cells. 
Molecular biomarkers can be used in designing of personalized medicine for 
diagnosis and treatment, identifying cellular changes at the DNA, RNA, biotrans-
former or protein level. Nanotechnology based devices can potentially screen 
disease biomarkers at high speed. The tools are developed by identifying biomark-
ers very specific for the disease that can lead to diagnostic tests. These nanobio-
technology-based diagnostic methods, which use direct DNA and protein analysis, 
can improve speed, accuracy and sensitivity over traditional molecular diagnostic 
techniques. Nanobiotechnology supports molecular diagnostics, and integration 
of diagnostics and therapeutics (theranostics) which accelerates personalized 
medicine [43]. Theranostic applications can help provide optimal treatments and 
characterize human genomic mutations between populations [44].
According to a report published by Grand View Research, Inc., the global market 
for pharmacogenomics (theranostics and complementary diagnostics) is expected 
to reach $18.3 billion by 2025. These approaches help provide cost-effective treat-
ment and add value to the process, of development. The benefits of using these tests 
for disease risk prediction, patient stratification, and treatment response monitor-
ing, over traditional methods are expected to provide significant progress in this 
market [45].
The role of genetics plays a vital role in theranostics, which provides successful 
and cost-effective therapeutic.
Pharmacological genetics, proteomics, and biomarker profiling based diagnosis 
using nanotechnology based platforms like liposomes, dendrimers, macromolecular 
nanoparticles, metal nanoparticles, quantum dots, and carbon nanotubes is provid-
ing vital information regarding disease pathology and its treatment. Quantum dots 
are stable particles which can be used as molecular labels to study the size and span 
of metastasis besides, predicting early signs of cancer and tracking the effective-
ness of drugs targeting the disease. Genzyme Corporation has discovered EGFR 
mutation detection kits that can be used to diagnose non-small cell lung cancer 
(NSCLC) [46].
6. Multiple genes interactions on treatment response
Multiple genetic interactions also termed as polygenic inheritance interconnects 
biological processes and their functional relationships that cause phenotypic devia-
tions and multiple genetic mutations [47]. A retrospective study of 108 Chinese 
patients with metastatic gastric cancer found nine genes involved in DNA repair 
(ERCC1, ERCC2, and XRCC1), detoxification of oxaliplatin (GSTP1 and GSTT1), 
and fluoropyrimidine metabolism (MTHFR) and these can be used to predict 
clinical response and survival [48]. Similarly, the Mayo Clinic has issued drug-gene 
pair alerts on 17 drug-gene pairs: Abacavir HLA-B*57:01, Allopurinol HLA-B*58:01, 
Carbamazepine HLA-B*15:02 and HLA-A*31:01, Citalopram CYP2C19,Clopidogrel 
CYP2C19, Codeine CYP2D6, Escitalopram CYP2C19, Fluoxetine CYP2D6, 
Fluvoxamine CYP2D6, Paroxetine CYP2D6, Simvastatin SLCO1B1, Tacrolimus 
CYP3A5,Tamoxifen CYP2D6, Thiopurines TPMT, Tramadol CYP2D6, Venlafaxine 
CYP2D6,Warfarin CYP2C9 and VKORC1 which will help physicians treat patients 
on the basis of the genetic test in response to the alert. These evidence-based 
guidelines were established by the Consortium for the implementation of clinical 
pharmacogenomics [49].
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7. Pharmacogenomic based diagnosis of cancer
Various cancer portals have been developed for tumor gene profiling and are 
 serving as a powerful tool for discovering and implementing personalized cancer 
treatments. Large-scale translational bioinformatics and cancer genomics platforms 
use multi-omics datasets to provide insight into genomic alternations and precision 
medicine strategies. Development in tools for statistical, mathematical and compu-
tational modeling help collect genomic information for molecular profiling, clinical 
responses to drugs, research on clinical trials, and identification and development 
of innovative therapies. Transcriptome data from melanoma exsons pretreated with 
ipilimumab was studied to study the effect of pretreatment on activity of tumor-
specific new antigens including mutation loading, new antigen loading, and cytolysis 
in the tumor microenvironment [50]. The Cancer Genome Atlas (TCGA) study 
performs molecular subtyping of the breast, colorectal and endometrial cancers. 
Furthermore, TP53 inactivation, MYC proliferation and dysregulated cell cycle 
checkpoints have been demonstrated through TCGA studies [51]. The role of phar-
macogenomics is more pronounced in oncology as compared to other diseases and 
is indicating that inherited differences in genes affect the body’s response to medica-
tions. Pharmacogenetics has revolutionized cancer treatment by genotyping patients 
in clinical settings that promote the best chemotherapeutic regimens and drug doses 
with maximum efficacy and minimal risk of toxicity. The Pharmacology Genomics 
Resources (PREDICT) program for enhanced decisions in care and treatment initiated 
by Vanderbilt University has simplified consistent dosing. Pharmacogenomic data 
identified for application in diagnosis and treatment has been shown in (Table 3).
S.no Pharmacogenomic data Diagnostic/Treatment Protocol Reference
1. Dihydropyrimidine 
dehydrogenase 
(DPYD) genotype and 
fluoropyrimidine dosing
The DPYD gene sequencing and it’s variant has 
been significantly analyzed by polymorphism 
(G to A intron 14 (inv14 + 1G > A or 
DPYD*2A; exon skipping mutation). Dosing 
of fluoropyrimidine depends on genotyping 






(MTHFR) is an essential regulator of folic 
acid and homocysteine  metabolism. In 
epilepsy, the concentration of 5-methyl-
THF in CSF should be monitored. The 
CSF concentration of 5-methyl-THF is 
significantly reduced in most early-onset 
patients due to restricted transport of folic 
acid through the blood-CSF barrier and 
increased demand for choline for meningeal 
biosynthesis resulting in severity of the 





The prodrugs azathioprine, 6-mercaptopurine 
(6-MP) and thioguanine (TG) are inactivated 
by TPMT and methylated to produce TG active 
nucleotide (TGN). 6-MP is biotransformed 
to methylthionosin 5-prime monophosphate, 
which causes inhibition of de novo purine 
synthesis and can cause toxic effects. TPMT 
gene genotyping is used for thiopurine dose 
assessment in myelosuppression. TPMT test 





8. Pharmacogenomic diagnosis for cardiac diseases
Clopidogrel is used in the acute coronary syndrome patients, exhibits variable 
response in patients due to *2 loss-of-function variant in CYP2C19 as it encodes 
hepatic cytochrome P-450 2C19 enzyme which is important for clopidogrel 
bioactivation. Similarly, interindividual variation in response to warfarin is due 
to polymorphisms in VKORC1 and CYP2C9 and has been led to revision of dosing 
guidelines for patients by USFDA. Variant of SLCO1B1, which encodes a hepatic 
uptake transporter, is associated with risk of myopathy with high-dose (80 mg/d) 
simvastatin [59]. Genetic mutations in thiopurine S-methyltransferase (TPMT), 
an enzyme that metabolizes azathioprine, result in higher concentration of the 
azathioprine active metabolite. Combining the immunosuppressant azathio-
prine and the enzyme thiopurine S-methyltransferase, is used to prevent heart 
S.no Pharmacogenomic data Diagnostic/Treatment Protocol Reference
4. Uridine diphosphate 
glucuronosyl transferase 
(UGT) genotype and 
irinotecan
Irinotecan is activated to SN-38. UGT1A1 
family is involved in glucuronidation of 
SN-38 and bilirubin. Variation in the number 
of TA dinucleotide repeats in the TATA 
element of the UGT1A1 promoter region, is 
associated with reduced gene expression as 
well as diminished enzyme activity
[55]
5. Glutathione S-transferases 
gene polymorphism and 
platinum compounds
Glutathione S-transferase (GST) constitutes a 
family of enzymes involved in detoxification 
of foreign bodies’, including cisplatin-based 
chemotherapy. Genetic polymorphisms in 
GST have shown altered efficacy or toxicity 
in patients with NSCLC (more specifically 
GSTP1 is associated with improved response 
to therapy)
[56]
6. ATP-binding cassettes 
(ABCB1, ABCC2, ABCG2)
The ABCB1 gene encodes P-glycoprotein. 
Overexpression of this glycoprotein leads to 
resistance to specific anti-cancer therapies. 
There are two synonymous SNPs (C1236T 
for exon 12 and C3435T for exon 26) and 
one non-synonymous SNP (G2677T for 
exon 2), which appear to be regulated 
by MDR1 * 2 haplotypes, P-glycoprotein 
upregulation and drugs. ABCG2 (Breast 
Cancer Resistant Protein) and ABCC2 are 
involved in irinotecan’s metabolism and alter 
the properties of irinotecans.
[57]
7. X-ray cross complementing 
group 1 (XRCC1)
XRCC1 is a DNA repair protein. It is encoded 
by the XRCC1 gene in humans. SNPs 
(1301 G > A; Arg399Gln) result in mutations 
in base excision ability and increased cancer 
risk. Negative expression of XRCC1 makes 
tumors more sensitive to platinum-based 
chemotherapy. Detection of XRCC1 
expression in patients with gastric cancer 
can provide clinical guidance in choosing the 
optimal adjuvant for therapy.
[58]
Table 3. 
Pharmacogenomic data identified for application in diagnosis and treatment.
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transplant rejection [60]. Sufficiently robust and predictive genetic information 
can be used to guide clinical decisions [61]. The European Pharmacogenetics 
of Anticoagulant Therapy (EU-PACT) found a significant association between 
PGx-guided warfarin dosing [62]. The genes most strongly associated with 
beta-blocker response are the β-1 adrenergic receptor (ADRB1), the α-2C adren-
ergic receptor (ADRA2C) and the G protein-coupled receptor kinase-5 gene 
(GRK5). The ADRB1 gene has two common non-synonymous single nucleotide 
polymorphisms, p.Ser49Gly and p.Arg389Gly, associated with different responses 
to beta-blockers in hypertension and coronary heart disease [59]. The genome 
aggregation database maintains archives the various gene variants. Guidelines 
for 27 drug-gene pair has been issued by Pharmagenetics Implementation 
Consortium, and includes data related to drug metabolizer phenotypes. (exten-
sive metabolizer/slow metabolizer), poor/ultrafast metabolizer, expected rapid 
metabolizer with a particular diplotype, expected effect size, availability of 
alternative therapies, and results of drug ineffectiveness or toxicity [63].
9. Pharmacogenomic diagnosis for brain disorders
Only 30–40% patients with central nervous system disorders respond conven-
tional drugs. Around 60–90% of variability in drug response is due to pharmaco-
genetic and pharmacogenomic factors. Approximately 60–80% of CNS drugs are 
metabolized via enzymes of the CYP gene superfamily. Neuroleptics are the major 
substrates of CYP1A2, CYP2D6 and CYP3A4 enzymes. Antidepressants are essen-
tial substrates for CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4 and benzodiaz-
epines are vital substrates of CYP2C19, CYP2D6 enzymes. Adoption of genomic 
medicine have proven to be prognostic tools to accelerate diagnostic accuracy in 
CNS disorders’ etiology and develop novel biomarkers to personalize treatments 
via pharmacogenetic and pharmacogenomic procedures for drug development and 
clinical practice [64].
10.  Role of nanotechnology and pharmacogenomics in the treatment of 
diseases
Advances in molecular pharmacology, genomics and nanotechnology are 
providing enriching clinical results by meticulously highlighting pathogenesis 
pathways, empowering the capacity for clinical diagnosis, and improving the 
outcome of drug delivery [65]. Supported by the sophisticated target-guided 
nanodevices, the intricate genomic information is being incorporated into clini-
cal practice to evaluate complex diseases such as cardiovascular diseases, type 
2 diabetes, asthma, cancer and degenerative disorders [66]. Presence of unique 
genetic variants has been found to be instrumental in predisposing particular 
individuals to the onset and development of diseases. Nanotechnology based drug 
delivery systems have developed specialized technical frameworks for the exploi-
tation of genomic knowledge, so as to reduce the risk of disease initiation and 
progression and drug toxicity [67]. Pharmacogenomics highlights the interplay of 
the role of genes in disease etiology, disease pathophysiology, disease biomarkers, 
drug targets, drug effects, and the fate of drugs inside the body. The integrated 
application of pharmacogenomics and nanotechnology will provides better thera-





Pharmacogenomics emerged as a science which highlighted the differences in 
drug response to differences in genetic makeup in particular populations/various 
ethnic groups. It is the science of genetic polymorphism (genetic variance) that is 
responsible for variability in drug response and is used as a useful method to assess 
the association of disease-gene, and gene-drug on drug response based on the 
human genome. Drugs are formulated and designed to counteract medical condi-
tions and cure ailments, but drugs often fail to demonstrate their beneficial impact 
in certain patients, resulting in adverse drug events. This drug response variability 
may be due to genetic differences [69]. The research of hereditary variability 
in drug receptors or target pathways, heterogeneity in genes that encode drug-
metabolizing enzymes or drug transporters, and genetic variation in genes that 
indirectly affect drug reaction are part of Pharmacogenomics. The main objective 
of pharmacogenomics is to recognize how genetic differences affect therapeutic 
efficacy and this knowledge can be used experimentally to personalize the selection 
of medications and their doses to improve efficacy and safety.
Pharmacogenetic tests have historically focused on specific candidates selected 
based on our understanding of the pharmacokinetics of the drug, and drug 
response variability found in patients receiving the medication. Initially, family 
experiments were used to determine the hereditary existence of inter-individual 
variations in the disposition of drug or effect of medications, which was then used 
to understand the genetic cause for monogenic traits. Pharmacogenomics can be 
seen as a wider approach to elucidate the abundance of genes that are important 
to pharmacology, including the implications of genetic differences in single genes, 
the relationship between genes in diverse pharmacological pathways, the pheno-
type that arises from these differences, and the impact of the phenotype on drug 
response. Its main characteristics are high-throughput genomic studies in conjunc-
tion with their significance to particular drug responses only as target phenotype 
(i.e., sequence variants in DNA, gene exposition analysis, etc.). The structural 
and functional genomics analysis (Figure 1) can be used to understand the use of 
therapeutic drugs for increased efficacy (with reduction in toxicity) for dosage 
personalization and new drug development [70]. The structural pharmacogenom-
ics explores the structural difference between individuals’ genes while functional 
genomics evaluate the functional modifications induced by structural variation 
in the genome. Variations in genes are responsible for the variation in particular 
functional process inside the body via change in the nature of protein synthesized. 
Any disorder or deformity may also result due to these functional changes. Both 
structural and functional pharmacogenomics are effective in predicting, recogniz-
ing genetic markers of disease, and planning and optimizing drug therapy in the 
treatment of that disease [71].
Extremely penetrating monogenic features are several of the genetic poly-
morphisms characterized to date that affect drug reaction in humans: hereditary 
variations in a specific gene have such a significant effect on the pharmacokinetics 
or pharmacodynamics of a drug that cross changes in one gene have a clinically 
relevant effect on drug response. “These are pharmacogenetics’ “low-hanging 
fruit“. However, certain proteins decide the efficacy of certain medications, and 
hybrid genetic polymorphisms can be identified to determine therapeutic effi-
cacy of several genes along with nongenetic factors. Therefore, new methods are 
required to classify the appropriate genes, genetic polymorphisms, mechanisms, 
and processes and; their association with a given drug. The different techniques 
currently being utilized are genome-wide haplotype analysis, gene regulation 
tests and proteomic techniques, as well as “candidate gene” approaches focused on 
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established pharmacokinetic and pharmacodynamic considerations. These methods 
are likely to be important for studies that seek to elucidate polygenic determinants 
of drug response, with emerging predictive and biological (pathway) models and 
quantitative genotyping in certain target tissues. Broad clinical trials with uniformly 
treated and routinely characterized patients, high-throughput genomic approaches, 
and advanced bioinformatics simulations would entail the clinical validity of 
these polygenic models. These experiments aim to create a new range of molecular 
diagnostics (i.e. genotypes) that can be used to enhance drug delivery by reducing 
toxicity and maximizing efficacy [72].
Nanotheranostics is the field where pharmacogenomics is used in the delivery of 
drugs for personalized medicines. It is a hybrid of drug therapies and diagnostics. 
Pharmacogenomics provides an excellent method to quantify several parameters 
relating to the disorder and its severity, together with treatment, so that medicine 
can be tailored on the basis of an individual’s genotype. Nanotechnology offers 
a possibility for the development and design of therapeutic strategies, which are 
capable of concurrently detecting genetic biomarkers for disease along with ongo-
ing drug therapy. Nanotechnological materials such as gold-based nanomaterials, 
Figure 1. 
Structural and functional pharmacogenomics analysis.
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magnetic nanomaterials, polymeric nanomaterials, carbon-based nanomaterials, 
silica-based nanomaterials, composite nanomaterials and quantum dots may be 
used to build such drug delivery systems [73, 74].
10.2 Role of Pharmacogenomics in the identification of drug targets
Structural Pharmacogenomics aims to recognize and verify disease-relevant 
targets for therapeutic activity (target biomarker) like the EGFR signaling 
system, PI3K, RAF, MAPK, KRAS AKT markers for various forms of cancers. 
Pharmacogenomics compares the target biomarkers with disease processes to create 
a connection between the disease and the biomarker of the experiment, which then 
helps to define the drug molecule for such a target [75, 76]. Specific genome targets 
like enzymes, drug carriers, proteins, nucleic acids, chromosomes, cell surface 
proteins, ion channels, and other bio-molecules contributing to the pathophysiol-
ogy of the disease have been provided by human genome sequencing. Such possible 
causes to the pathophysiology of the disease can serve as target sites for drug action 
(druggable targets). Thus, the pharmacogenomics concept can be used in target rec-
ognition, genotyping, structural elucidation, and target confirmation that improve 
safety and efficacy of medicines. Sequencing of the target genes can be used in the 
discovery and validation of lead compounds [77, 78].
10.3 Nanotechnology towards making possibility of personalized medicine
Nanotechnology is the development and utilization of materials, devices and 
processes by manipulating matter at the nanometer range, i.e. at the level of atoms, 
molecules, and supermolecular structures. The application of nanotechnology in 
life sciences is in molecular diagnostics, drug discovery, drug delivery and nano-
medicine development. The combination of nanotechnology with personalized 
medicine has created unparalleled and unique opportunities to improve the treat-
ment of many serious diseases. Medicine has been profoundly impacted by this con-
cept over the last decades, shifting its attention to the molecular level under which, 
applications of nanotechnology as a quickly emerging field appear to fit needs on 
this size scale. In this reference, nanoparticles offer unique benefits in the design 
of nanomedicine due to their small size, flexibility, increased surface-to-volume 
ratio and multi-purpose ligand surface modification in order to obtain targeting of 
cells/tissues. Nanomedicine is also meant to offer immediate, precise and efficient 
diagnosis and treatment. In this way, the balance between maximum therapeutic 
efficacy and lower toxicity is significantly promoted [79, 80].
As the nanomedicine market has expanded exponentially, the most promis-
ing technologies and applications for personalized medicine can be identified. 
Individuality of a person is often expressed in his pathophysiology. In the same 
extent genes define, the identity of an individual, genetic heterogeneity that can 
identify the disease phenotype and its drug response. It is reported that each drug 
has different effects on different types of peoples. Whether in terms of efficacy and 
safety of these drugs, they show differential behavior due to the complex nature 
and heterogeneity of individuals (both patients and diseases). With a sound and 
detailed knowledge of genomics and proteomics and the development of a novel 
and innovative technology and patient-based molecular profiling, the promise of 
nanomedicine has opened the path to the future of personalized medicine [80, 81].
Personalized medicine literally means prescribing of particular medications 
that are ideally suited to the person. Personalized medicine is the perfect way to 
incorporate modern biotechnology into medicine in order to improve understand-
ing of disease pathomechanism, molecular identification and clinical application. 
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Nowadays, nanotechnology and genomics fuel expertise and creative practices, 
allowing both pharmacological strategies and therapeutics measures to be imple-
mented on a personal basis, i.e. designing personalized medications (Innovative 
Drugs), improving targeted drug delivery and pharmacotyping techniques to the 
clinical environment for diagnosis and treatment of disease as shown in (Figure 2). 
“Pharmacotyping” is characterized as the prescription drug mechanism by which 
clinical and genotyping data are used to instruct physicians to design drug dose regi-
mens for particular patients. These approaches require a comprehensive genetic and 
molecular history of each patient, which leads to the discovery of specific biomark-
ers that might influence the progression of the disease and the response to treatment. 
Personalized medicine is also not only restricted to the study of biomarkers and 
genetic polymorphisms, but also depends on the development of disease identifica-
tion techniques and estimation of therapeutic responses [73]. Thus, understanding 
Figure 2. 
Integrated approach of nanotechnology and pharmacogenomics to improve safety and efficacy of drugs.
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of nanotechnology and genomics could handle the disease and drug response of 
patients in the form of personalized medicines. In addition, recent developments in 
nanotechnology have certainly provided the perfect environment for the emergence 
of personalized medicine as the new approach in the diagnosis of diseases and drug 
therapy.
10.4 Nanoparticles in personalized medicine
Because of their exploratory features, nanoparticles facilitate the molecular 
targeting of medicines. Recent studies offered detailed information on the relation-
ship of NPs with biological processes in order to promote their use for nanother-
anostics diagnosis, imaging and drug delivery. Today, nanotheranostics have been 
developed to monitor transcription and translation of genes, recognize cancer 
cells, control the proliferation of T cells, and manage blood sugar levels. Moreover, 
blood urea levels can be detected by an implant and normal levels can be restored. 
Another implant was created for artificial insemination that injects bull spermato-
cytes into the bovine ovary by identifying luteinizing hormone levels, especially 
during ovulation. Any disorder can be treated at the cellular and molecular level by 
detecting particular biochemical parameters [79]. While several experiments have 
been performed, relatively few pharmaceutical drug products have been developed 
as nanotherapeutics in the pharmaceutical market, indicating the uncertainty 
of formulating active compounds in these formulations. A PEGylated liposome 
doxorubicin medication called Doxil, approved for therapeutic use by the FDA, is 
the most popular example of nanoparticle technology for clinical use. The principle 
of PEGylation was first developed as a means for recombinant protein drugs to 
improve their circulation and stability. Another FDA approved effective nanopar-
ticle application is Abraxane, in which paclitaxel is formulated with albumin. In 
an attempt to merge nanoscale therapeutic and diagnostic modalities, separate 
nanotheranostic agents have been designed to provide flexible platforms for the 
simultaneous delivery of diagnostics and therapeutics [73].
However, many new materials have arisen as theranostic agents such as gold 
nanoparticles, carbon nanotubes, metal organic frameworks and iron oxide 
nanoparticles; problems of safety and bio - compatibility and unspecified toler-
ance and toxicity need to be evaluated in the clinic. Regardless of these drawbacks, 
nanotheranostics seem very optimistic to develop personalized medicine [79].
11. Personalized nanomedicines
Personalized nanomedicine may be described as the management of a patient’s 
disease or drug response by the use of nanomedicine in combination with clinical 
and molecular expertise (e.g. genomics, proteomics, epigenomics and metabo-
lomics) as well as bioinformatics techniques to produce the best possible medi-
cal treatment for that person. In addition, by integrating nanotechnology and 
genomics expertise, personalized nanomedicine may create enhanced profiles for 
particular demographics and particular patients for prognosis, diagnosis and drug 
therapy, as well as surveillance through medical science and clinical management 
(Table 4) [81].
The combination of nanotheranostics with pharmacogenomics will take us to 
the next level of therapeutics. On one hand, the concept of pharmacogenomics 
is the latest model research, which has tremendous implications throughout the 
field of medical science and drug development at genomic and molecular level; 
moreover, a great deal of work is needed to investigate the maximum capabilities of 
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this method in the clinical field. Theranostics, on the other hand, is the technique of 
early phase diagnosis or disease pathogenesis, combined with concurrent treatment 
based on a single unit operation diagnosis profile. This not only increases patient 
health with optimum clinical performance, but also saves significant amounts of 
money by minimizing excessive care costs. This approach is of significantly more 
useful in the treatment of life-threatening chronic diseases like cancer, hyperten-
sion, Alzheimer disease, and can be implemented to many other ailments [68].
11.1 Personalized nanomedicine in the treatment of cancer
The advancement of personalized nanomedicine is a useful technique in the 
cancer therapy. Personalized oncology is raising new prospects for the elimination 
of cancer incidence by specifically targeting anticancer medicines to cancerous 
cells, target areas on the cell surface and inside the tumor microenvironment. 
Nanooncology has succeeded in improving the specificity and efficiency of cancer 
therapies, both by promoting the development and distribution of medications and 
by reducing clinical toxicity and serious incidents [82]. Personalization of cancer 
treatment is focused on a deeper knowledge of the pathogenesis at the molecu-
lar scale and nanomedicine can play a significant role in this direction. Several 
nanobiotechnology-relevant components of personalized cancer treatment are 
given in (Figure 3) [83]. Nanobiotechnology has the ability to enhance early cancer 
diagnosis and enhance personalized cancer treatment. Molecular diagnostics is the 
most important aspect of personalized medicine, and nanobiotechnology can play a 
significant role in its refinement [84].
Dendrimers are a class of nanoscale, core-shell, three-dimensional structures 
that can be synthesized precisely for a variety of uses. Specialized methods in chem-
istry allow detailed control over the dendrimer’s physical and chemical proper-
ties. They are most effective in the delivery of drugs, but they can also be used to 
produce new pharmaceuticals with emerging technologies. With several therapeutic 
target, polyvalent dendrimers interact simultaneously. They can be transformed 
into new-targeted therapeutics for cancer. Using complementary DNA oligonucle-
otide primers, dendrimers may be covalently linked to various bio-functional 
groups, such as folic acid, to create clustered molecules attacking cancer cells that 
overexpress the high affinity folate receptor [85]. Endothelial αvβ3-Integrin-
targeted paramagnetic nanoparticles are being used to identify very limited angio-
genesis area linked with tumors of nascent melanoma [86]. Nanobodies (Ablynx) 
are the smallest intact antigen binding fragments that have the full antigen binding 
capacity of natural heavy-chain antibodies. Nanobodies are prospective era of 
antibody-based treatments as well as diagnostic tools for diseases like cancer. 
Advantages of Personalized Nanomedicines
Personalized nanomedicine is in nano-scale size range
Personalized nanomedicine offers tunability and flexibility
Offers possibility of using labile substances such as siRNA
The active concepts of personalized nanomedicine: encapsulation and safety
Targeted delivery to organs/ tissues/ cell compartments
Probability of responding to a need of specific patient group
Adapting patterns of treatment to each patient (e.g., dosage, frequency, etc.)
Table 4. 
Advantages of personalized nanomedicines.
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Nanobodies have a relatively high specificity and low endogenous toxicity. They 
can tackle therapeutic targets that are not readily detected by traditional antibodies 
such as enzyme active sites. Nanobodies have the ability to be produced as personal-
ized cancer therapies [87]. Nanotechnology is revolutionizing the treatment of 
cancer as it can alter its diagnosis, clinical path, and prognosis. Before treatment, 
cancer molecular profiling may be extremely prognostic and predictive of clinical 
responses or recurrence, encouraging the most effective treatment to be prescribed 
with each specific cancer.
11.2 Personalized nanomedicine for targeting CNS diseases
Central nervous system (CNS) disorders are increasingly worldwide due to 
changing demographics. Three factors make this field especially challenging as, 
pathogens are slowly evolving and impossible to diagnose early or anticipate, 
response to medication is highly dependent on the individual patient and always 
needs to be personalized, and drugs must pass the blood brain barrier [88]. 
Therapeutic agents commonly used to treat CNS diseases have shown considerable 
efficacy. However, the failure of these medicines to pass the blood–brain barrier 
(BBB) and the inefficacy of technology to ensure localized delivery of drugs in 
disease-specific areas of the brain have impeded full CNS disease management. 
Nanoparticle- based targeted drug delivery to the brain will play a significant com-
ponent in designing personalized treatment of neurological disorders by enhancing 
molecular diagnosis and pathomechanisms. For CNS drug delivery system, differ-
ent types of nanoparticles (gold, silica, hydrogels, liposomes, magnetic nanopar-
ticles, etc.) have been investigated. Such examples of the use of personalized 
treatment-based nanotechnology to treat CNS diseases are as follows: [89].
Gene silencing technologies focusing on small interfering RNA (siRNA) have 
shown great potential for the treatment of brain-associated diseases. However, suc-
cessful and systemic delivery of siRNA to the brain appears difficult due to biologi-
cal challenges such as enzymatic depletion, short-lived circulation, blood–brain 
barrier (BBB), relatively low tissue penetration, cell endocytosis, and cytosolic 
transport. Nanotechnology provides an interesting opportunity to overcome these 
problems in the delivery of siRNA to brain in combination with chemical and 
biological alteration strategies [90].
Alzheimer’s disease (AD) is a major public health concern worldwide. The 
challenge in treating the disease is partly attributed to the uncertainty of the signs 
and symptoms, the still limited understanding of its pathways and the presence of 
Figure 3. 
Function of nanobiotechnology for personalized cancer treatment.
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latent, asymptomatic, condition. While several drugs are constantly screened in 
clinical trials for the treatment of Alzheimer’s disease, the unpredictable patient 
response and often-serious adverse effects provide space for development for per-
sonalized nanomedicine [91]. In a study involving AD, the brain region was irradi-
ated with low gigahertz electromagnetic fields after binding of gold nanoparticles 
to β-amyloid plaques. The energy level was quite low for healthy cells to be affected. 
This study can be used effectively in the treatment of CNS disorder involving 
protein aggregation [92].
A “nanozyme” consists of a composition of the nanoparticle, an enzyme and 
a moiety for recognition. In Parkinson’s disease (PD), oxidative stress degrades 
the main dopaminergic receptors in the brain resulting in inflammation. It is also 
assumed that catalyzing the enzyme might be beneficial in therapy. Nanozyme, 
encapsulating catalase, and macrophages extracted from bone marrow linked to 
a recognition moiety, when administered, showed that navigation of the nano-
zyme into the region of brain’s inflammation. As a result, better distribution and 
improved bioavailability are achieved through the BBB [93].
11.3 Personalized nanomedicine for cardiovascular diseases
The development of cardiovascular diagnosis is now being influenced by 
nanosystems that can both detect and treat disease with a targeted delivery system. 
Nanotechnology has the ability to significantly accelerate the acceptance of per-
sonalized medicines in area of cardiovascular research by allowing production of 
fast, multimode point-of-care identification of single nucleotide polymorphisms 
(SNPs). This will, in essence, include information on the dangers associated with 
the progression of particular coronary disorders and pharmacogenetic advice on 
appropriate treatment for individual patients. In order to be clinically effective, 
the ideal method would need to be convenient, reliable, capable of simultaneous 
calculation of multiple genotypes and capable of conducting the full study without 
user intervention [94]. The different approaches to nanomedicine used in the form 
of nanocardiology have been mentioned in (Figure 4).
The possibility of cardiovascular procedures for the treatment of cardiovascular 
disorders appears to be interconnected with nanosystems capable of providing 
pathological diagnosis and treatment by means of changeable and regulated 
targeted systems. The dual potential of nanoparticles for visualization and selective 
distribution of therapeutic drugs to patients with cardiovascular disease would be 
a great opportunity for personalized medicine. By combining target drug delivery 
and molecular imaging with magnetic resonance imaging, the functions of serials 
by expressing epitope can be identified. At the desired target, monitoring and treat-
ment validation will clear the way for individual treatments [95].
11.4 Personalized nanomedicine for bone disorders
Osteoporosis is the most common metabolic bone disorder, and osteoporosis 
susceptibility genes (ESR1, LRP5, SOST, OPG, RANK and RANKL) are involved 
in three biological pathways: the estrogen endocrine pathway, the Wnt/β-catenin 
signaling pathway and the RANK/RANKL/osteoprotegerin (OPG) pathway [96]. 
Estrogen plays an essential role in bone biology through binding to two different 
estrogen receptors (ESRs), ESR1 and ESR2. Women’s Health Initiative performed 
a randomized controlled trial of hormone therapy, in which oral conjugated 
0.625 mg equine estrogen with or without 2.5 mg medroxyprogesterone acetate was 
administerd and showed significant reduction in postmenopausal risk of osteo-
porosis [97]. Vascular endothelial growth factor A (VEGFA), is highly expressed 
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in osteocarcinoma (OS) and acts as an autocrine survival factor for tumor cell 
themselves. OS cell-specific aptamer (LC09) -functionalized PEG-PEI-Cholesterol 
(PPC) lipopolymer encapsulating CRISPR/Cas9 plasmids encoding VEGFA 
gRNA and Cas9 in both orthotopic OS and lung metastasis, showed effective 
VEGFA genome editing in tumor, decreased VEGFA expression and secretion, 
inhibited orthotopic OS malignancy and lung metastasis [98]. Zhang et al. evalu-
ated G-protein-coupled Receptor Kinase Interactor-1(GIT1), as a target for the 
treatment of osteosarcoma and suggested that knowdown of GIT1 inhibited cell 
invasion and VEGF release in vitro and suppressed tumor growth, invasion, and 
angiogenesis in vivo, and also resulted in downregulation of hypoxia-inducible 
factor1α (HIF1α) and extracellular signal-regulated kinase (ERK1/2) pathways [99].  
Moreover studies have shown that ALDH1B1, a subfamily of Aldehyde dehydro-
genases (ALDHs), is upregulated in OS. Silencing of ALDH1B1 could inhibit the 
growth of xenograft tumor and knockdown of the same has shown to cause cycle 
arrest in G1 stage of OS cell in vitro cycle. Moreover, inhibition of ALDH1B1 expres-
sion could increase the sensitivity of chemotherapy [100]. The siRNA nanocarriers 
of chitosan-folic acid efficiently transferred the astrocyte elevated gene-1 (AEG-1) 
Figure 4. 
Nanomedicine in the context of nanocardiology for cardiovascular disease management.
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into the osteosarcoma cells, and knockdown of AEG-1 resulted in the inhibition of 
tumor cell proliferation and invasion [101].
11.5 Personalized nanomedicine for kidney disorders
The development of highly accurate biomarkers is essential for optimizing the 
management of kidney diseases. Various biomarkers of kidney diseases have been 
identified using proteomic techniques. Sequencing and genotyping can also help 
diagnose and treat kidney stones, cystic kidney disease, glomerulonephritis, and 
chronic kidney disorder. Besides, the pharmacogenomics predictors can help pre-
dict early-onset chronic kidney disease (CKD). Allelism in basement membrane–
associated Fraser complex (FRAS1, FREM1, FREM2, GRIP1) is observed in CKD 
[102]. However, only a few of these biomarkers could be potentially used in clinical 
practice for development of personalized medicine. CKD273, has been validated 
and used in an interventional trial as a biomarker for early CKD detection, and has 
received a ‘Letter-of-support’ from the FDA [103].
The angiotensin-converting enzyme (ACE) gene encodes ACE, involved in the 
renin-angiotensin-aldosterone system and kinin–kallikrein pathway. ACE inhibitors 
are currently used in CKDs as renoprotective which reduce proteinuria and blood 
pressure. The genotyping approach is being used in patients with CKDs or trans-
plantation, to treat patients who are nonresponsive to drugs. The polymorphism of 
Immunoglobulin Fc receptor (FcϒRIIIa) increases rituximab affinity by 10 folds 
and such polymorphisms may influence the efficacy of drugs. From transcriptome 
study on peripheral blood mononuclear cells (PBMCs) of uremic patients, the genes 
macrophage migration inhibitory factor, IL-8 receptor β and chemokine ligand 12 
have been identified as potential therapeutic targets for reduction of inflamma-
tion in dialysis patients [104]. Gold (Au) and poly-actic-co-glycolic acid (PLGA) 
nanoparticles (NPs) loaded with fenoldopam (FD) targeted to dopamine-receptor 
type-5 (DR5) on primary cilia have been evaluated for the treatment of vascular 
hypertension in polycystic kidney disease (PKD) model through cilia targeting 
[105]. Podocytes play apivotal role in the progression of various kidney-related 
diseases. Vascular Cell Adhesion Molecule-1 (VCAM-1) expression is increased by 
podocytes upon TNFα-activation for upto 24 h and anti-VCAM-1 antibody can be 
employed as a ligand to facilitate the uptake of nanocarriers under inflammatory 
condition. Anti-VCAM-1-rapamycin-SAINT-O-Somes (lipid-based nanocarrier 
system) has been found to deliver the potent immunosuppressant rapamycin to 
TNFα-activated podocytes [106].
11.6 Personalized nanomedicine for gastrointestinal disorders
Functional gastrointestinal disorders (FGIDs) associated with impaired upper 
gastrointestinal (GI) due to delayed gastric emptying (GE), reduced gastric 
accommodation (GA), and functional lower GI symptoms including constipation-
predominant irritable bowel syndrome, pelvic floor dyssynergia, colonic inertia, 
diarrhea-predominant irritable bowel syndrome, bile acid diarrhea, or act as a 
specific target for personalized medication. Hence, gastric relaxants or central neu-
romodulators, prokinetics are being used for personalized medicines in Functional 
Gastrointestinal Disorders (FGIDs). Personalized nanomedicine integrated with 
pharmacogenomics relates drug pharmacokinetics and drug enzymatic activity, 
specifically of CYP2D6, 2C19 and 3A4, to treat patients with FGIDs [107].
Orally delivered micellar nanoparticles, loaded with indomethacin developed 
by Yoshitomi et al., has potent nitroxide radical and ROS scavenging activity to 
treat small intestinal disorders [108]. Similarly, colon targeted hyaluronan-cisplatin 
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conjugated nanoparticles (HCNPs) has been developed by Tsai et al. for colon- 
specific drug delivery [109]. Also, CD98 siRNA/polyethyleneimine (PEI)-loaded 
NPs developed by Laroui et al. has shown down-regulation of intestinal CD98 
for the treatment of colitis [110]. In addition, CS-TPP/IL-21 nanoparticles, 
Methotrexate loaded and folic acid conjugated guar gum nanoparticles (MTX-
FA-GGNP), and deoxycholic acid conjugated nanoparticles (DexDA) loaded with 
retinoic acid have shown beneficial results in colorectal cancer [111–113].
Nonalcoholic fatty liver disease (NAFLD), including steatosis, fibrosis, and 
cirrhosis, leads to hepatocellular carcinoma. The CYP enzymatic activity that 
metabolizes different drugs can be affected by NAFLD. Hence, personalized treat-
ment in all NAFLD patients is done through genetic profiling of the patient besides 
taking into account gender, environmental factors, diet habits, and CYP pattern to 
determine effective drug treatment. The polymeric nanoparticles such as the Smart 
Insulin L-490, a kind of personalized nanotheranostics, estimates patient glucose 
level and responds to the stimulus by releasing appropriate amount of insulin 
(Table 5) [123].
12. Future prospects
Regardless of contributions made by scientists, the adoption of pharmacogenetic 
testing in the clinical application has not been up to great extent [124]. The clinical 
Drug Name Nanoformulation Indication Phase* References
DaunoXome/
Daunorubicin
Liposome Acute myeloid leukemia, 
solid tumors, first-line 
























Liposome Malignant Mesothelioma Phase II [117]
DepoDur/
Morphine sulfate




Nanocrystal Schizophrenia Marketed [119]




Lipid nanoparticles Amyloidosis Phase III [121]
Tricor/Fenofibrate Nanocrystal Hypercholesterolemia Marketed [122]
Note: PEG: poly (ethylene glycol); PLA: poly (lactic acid), PM: Polymeric miscelles, NSCLC: Non-small cell lung 
cancer, siRNA: Small interference RNA.*www.clinicaltrials.gov
Table 5. 
List of nanomedicines under clinical evaluation to target various diseases.
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trial of Tailor PCI study on the drug clopidogrel may increase the testing rates but 
presence of cheaper alternatives that does not require any pharmacogenetic testing 
may reverse the scenario [1]. Genome wide association studies which purport to 
give the well replicated data on genetic risk factors for complex diseases support 
the future of advanced application of pharmacogenetics. These novel risk factors 
may serve as potential therapeutic targets for the newly developed drugs and proper 
information about the patient genotype for these vital targets may affect the art of 
prescribing these drugs [125, 126]. Owing to these technology advanced settings, it 
is more likely that the pharmacogenetic knowledge will be available routinely in the 
near future, which will affect the science of prescribing drugs.
13. Conclusion
Pharmacogenomics is progressing in the form of personalized medicines in the 
world today. The main purpose of personalized therapies is to improve healthcare 
through the application of emerging technology. In these innovations, nanotechnol-
ogy plays a key role with integration of pharmacogenomics to improve diagnosis 
and therapeutics at the individual level treatment. With this approach the introduc-
tion of personalized nanomedicine, has provided a major stimulus to the medicine 
and pharmacy disciplines to include advanced clinical therapies, disease manage-
ment, diagnosis, and delivery of drugs.
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